Over 50 million Americans, predominantly women, live with autoimmune conditions like rheumatoid arthritis, lupus, and multiple sclerosis. These diseases consume nearly 30 percent of pharmacy spend for self-insured employers. According to the Autoimmune Association, patients wait an average of 4.6 years for diagnoses, cycling through nearly five physicians, only to enter a system designed for symptom management rather than addressing root causes. Despite affecting more people than cancer and heart disease combined, autoimmune care remains fragmented and reactive. 

WellTheory is changing that, which is why we're leading WellTheory's $14M Series A. 

A New Model for Autoimmune Care

WellTheory has built an enterprise-grade platform purpose-built for autoimmune care, combining registered dietitians and board-certified health coaches with applied AI to personalize treatment and address root causes like nutrition, stress, sleep, and lifestyle. 

The economics are striking. Independent actuarial analysis shows average annual savings of $5,200 per autoimmune patient and $9,400 for those on biologics. Third-party analysis by Accorded found that the platform reduces imaging services by 71 percent, ER visits by 64 percent, hospital stays by 38 percent, and biologics utilization by 15 percent. For employers, autoimmune disease has become a top-two spend category after musculoskeletal care. This is health assurance at work: moving from reactive treatment to proactive, preventive care that bends the cost curve while improving lives. 

In 18 months, WellTheory has signed Fortune 500 clients and secured partnerships with regional and national payors. Customers have praised the platform as "on par with [high quality public digital health companies]," remarkable validation for an early-stage company.

CEO Ellen Rudolph built WellTheory from her own lived experience with autoimmune disease. We’ve been cultivating a relationship with Ellen given our long-standing interest in the autoimmune space, and she has clearly emerged as a market leader, exceeding our expectations from an execution standpoint. In under two years, she assembled a lean, high-performing team with the commercial instincts, clinical expertise, and technical depth to deliver exceptional care at scale.

The Opportunity Ahead 

Autoimmune disease represents a $150B+ annual market that’s expanding as new immunology drugs come to market. WellTheory's combination of proven outcomes, scalable care delivery, and AI-enabled efficiency positions it to define the category.

This is the future of health assurance: purpose-built platforms that intervene early, personalize care at scale, and align economic incentives with patient outcomes. By addressing root causes rather than managing symptoms, WellTheory has the potential to set a new standard of care. 

This financing round will fuel expansion of WellTheory’s clinical, technology, and sales teams, scale its biologics management program, and accelerate investment in AI-driven personalization. We look forward to the journey ahead with Ellen and the WellTheory team as they work to deliver better outcomes and lower costs for millions living with autoimmune conditions.